Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580557 | 0.91 | TSHR (0.43) | TSHRLMNAMAPTALOX15HCAR2 | |
| SCHEMBL17617132 | 0.91 | TSHR (0.43) | TSHRLMNAMAPTALOX15HCAR2 | |
| SCHEMBL1866475 | 0.91 | TSHR (0.43) | TSHRLMNAMAPTALOX15HCAR2 | |
| SCHEMBL13541326 | 0.91 | TSHR (0.43) | TSHRLMNAMAPTALOX15HCAR2 | |
| SCHEMBL18388349 | 0.83 | ALDH1A1 (0.39) | TSHRLMNAMAPTALOX15 | |
| SCHEMBL6896971 | 0.83 | ALDH1A1 (0.39) | TSHRLMNAMAPTALOX15 | |
| SCHEMBL17788570 | 0.80 | FOLH1 (0.33) | MAPT | |
| SCHEMBL14033153 | 0.80 | TSHR (0.33) | TSHRLMNAMAPT | |
| SCHEMBL2607995 | 0.79 | — | — | |
| SCHEMBL13153226 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | SERPINB1, KLKB1, MPO | TSHR 2435/4885LMNA 1572/4885MAPT 1912/4885 |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | TSHR 2435/4885LMNA 1572/4885MAPT 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.